• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  2. Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada

    Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada

  3. Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

    Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

  4. CORRECTING and REPLACING APAC Will be the Fastest Growing Market for Global Warehousing Services Market Until 2020, Reports Technavio

    CORRECTING and REPLACING APAC Will be the Fastest Growing Market for Global Warehousing Services Market Until 2020, Reports Technavio

  5. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  6. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  7. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  8. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  9. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.